<div id="readability-page-1"><p>Northwestern Mutual Wealth Management Co. grew its position in shares of  Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 24,930.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 101,373 shares of the company's stock after buying an additional 100,968 shares during the period. Northwestern Mutual Wealth Management Co. owned approximately 0.36% of Medpace worth $56,936,000 at the end of the most recent quarter.</p><ul><li>Can Medpace Stock Keep up this Pace?</li></ul><p>Other large investors have also recently added to or reduced their stakes in the company. Cibc World Market Inc. purchased a new stake in shares of  Medpace during the 3rd quarter valued at about $5,033,000.  Wealth Enhancement Advisory Services LLC boosted its holdings in shares of  Medpace by 150.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company's stock worth $8,080,000 after buying an additional 9,117 shares during the last quarter.  Capital Fund Management S.A. boosted its holdings in shares of  Medpace by 129.5% in the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company's stock worth $16,665,000 after buying an additional 18,287 shares during the last quarter.  Dorsey Wright &amp; Associates purchased a new position in shares of  Medpace in the third quarter worth approximately $5,082,000.  Finally, Baillie Gifford &amp; Co. boosted its holdings in shares of  Medpace by 12.0% in the third quarter. Baillie Gifford &amp; Co. now owns 584,796 shares of the company's stock worth $300,679,000 after buying an additional 62,503 shares during the last quarter. Institutional investors own  77.98% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts recently issued reports on the stock. Jefferies Financial Group raised shares of Medpace from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $560.00 price objective on the stock in a report on Friday, February 13th. Wall Street Zen downgraded shares of Medpace from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 25th. BMO Capital Markets dropped their price objective on shares of Medpace from $460.00 to $400.00 and set a &#34;market perform&#34; rating on the stock in a report on Friday, April 24th. Mizuho  set a $582.00 price objective on shares of Medpace in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada dropped their price objective on shares of Medpace from $522.00 to $484.00 and set an &#34;outperform&#34; rating on the stock in a report on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has an average rating of &#34;Hold&#34; and a consensus target price of $467.08.</p><p><b>View Our Latest Report on MEDP</b></p><h2>Medpace Price Performance</h2><p>Medpace stock opened at $415.27 on Monday. The stock has a market cap of $11.86 billion, a P/E ratio of 26.10, a PEG ratio of 2.11 and a beta of 1.19. Medpace Holdings, Inc. has a 1 year low of $287.17 and a 1 year high of $628.92. The firm's 50 day moving average price is $463.68 and its 200-day moving average price is $524.55. </p><p>Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million for the quarter, compared to analysts' expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The company's revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter last year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS.  As a group, equities analysts expect that  Medpace Holdings, Inc. will post 17.04 EPS for the current year. </p><h2>Insider Activity</h2><p>In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 20.50% of the stock is currently owned by insiders. </p><h2>Key Medpace News</h2><p>Here are the key news stories impacting Medpace this week:</p><ul>   <li><span>Negative Sentiment: </span>Multiple law firms issued fresh reminders about an already filed class action alleging Medpace misled investors during the April 22, 2025 to February 9, 2026 period, with lead-plaintiff deadlines approaching in early June. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>New and repeated class-action notices are keeping Medpace’s alleged investor-harm claims in the spotlight, which can weigh on sentiment and increase legal overhang for the stock. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>Coverage specifically highlighting Medpace’s backlog disclosures and governance suggests investors are scrutinizing the quality of the company’s operational reporting, adding to uncertainty around future performance. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>Additional law firm notices from Faruqi &amp; Faruqi, The Gross Law Firm, BFA Law, Rosen, Pomerantz, DJS Law Group, and Schall keep the class action front and center, reinforcing a negative near-term narrative for MEDP. <i></i><span>Article Title</span></li> </ul><h2>Medpace Profile</h2> (Free Report)<p>Medpace Holdings, Inc <span>NASDAQ: MEDP<span></span></span> is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.  </p><p>Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Medpace</li><li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li><li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li><li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li><li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li></ul><p><strong>Want to see what other hedge funds are holding MEDP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medpace Right Now?</h2><p>Before you consider Medpace, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.</p><p>While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MEDP

SBIO

<p>Northwestern Mutual Wealth Management Co. significantly increased its stake in Medpace Holdings, Inc. by 24,930.4% during Q4, acquiring 100,968 shares, bringing its total to 101,373 shares valued at approximately $56.9 million. Institutional investors now own 77.98% of Medpace. Analysts have mixed ratings on the stock, with a consensus target price of $467.08. Medpace reported strong Q1 earnings, beating estimates with $4.28 EPS and $706.6 million in revenue, up 26.5% year-over-year.</p>

Market Beat

Medpace

iShares US Medical Devices

ALPS Medical Breakthrough

SPDR S&P Health Equip

Health Care Select Sector SPDR

Jefferies Financial

Mizuho Financial

Mizuho Financial Group, Inc.

ROYAL BANK OF CANADA

Northwestern Mutual Wealth Management Co. Purchases 100,968 Shares of Medpace Holdings, Inc. $MEDP